In May, a historic moment in science and medicine was captured in a single photo that circulated across news outlets ...

The idea that a single-celled bacterium can defend itself against viruses in a similar way as the 1.8-trillion-cell human ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Science and medicine are incredibly amazing. Thanks to modern science and medicine, we now have lifespans far beyond our Dark ...

Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...

A CRISPR-Cas9-based therapy targeting the gene encoding transthyretin greatly reduced transthyretin levels in patients with ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $74.89, moving -2.46% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.28% for ...

CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest ...

If you have been staring at CRISPR Therapeutics stock lately, wondering whether it is time to buy, hold, or rethink your position, you are far from alone. Over the past week, the stock has surged 16.1 ...

We expect investors to focus on the sales performance of CRISPR Therapeutics’ CRSP sole-marketed product, Casgevy, and other pipeline updates when the company reports its second-quarter 2025 results.

Science and medicine are incredibly amazing. Thanks to modern science and medicine, we now have lifespans far beyond our Dark Age predecessors, living until ripe old age and enjoying the fruits of our ...